At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 18 enrolled
Drug / intervention
Maraviroc +3 moredrug
Likely dose
Maraviroc 300 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Phase 4 Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects
In Brief
A Phase 4 clinical trial evaluating Maraviroc and Raltegravir for Healthy. Completed, enrolled 18 participants across 1 site.
Detailed Summary
An open label study to evaluate an interaction between maraviroc and raltegravir in healthy subjects.
Study Details
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
Primary CompletionMar 2008
First PostedApr 2008
TodayJul 2026
First PostedApr 25, 2008
Enrollment StartFeb 1, 2008
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 18.2 years ago
Interventions
Maravirocdrug
300 milligrams(mg) every 12 hours Days 6-11
Maravirocdrug
Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
Raltegravirdrug
Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
Raltegravirdrug
400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5